Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Metagenomi Inc MGX

Healthcare Biotechnology
Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. Its genome editing toolbox includes nuclease-based genome editing, base editors, RNA-mediated integration, including prime editing, and DNA-mediated integration, such CRISPR-associated transposases. The company has a collaboration and license... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:MGX)

Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference

GlobeNewswire December 1, 2025

Metagenomi to Present at Jefferies Global Healthcare Conference in London

GlobeNewswire November 17, 2025

Metagenomi Reports Third Quarter 2025 Financial Results and Announces Strategic Pipeline Prioritization and Leadership Updates

GlobeNewswire November 11, 2025

Metagenomi Presents New Preclinical Data from MGX-001 Hemophilia A Program Supporting Advancement into Clinical Development

GlobeNewswire November 11, 2025

Metagenomi Reports Business Updates and Second Quarter 2025 Financial Results

GlobeNewswire August 12, 2025

Metagenomi Appoints Laurence Reid, PhD to its Board of Directors

GlobeNewswire August 11, 2025

Metagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASGCT Annual Meeting 2025

GlobeNewswire May 14, 2025

Metagenomi Reports Business Updates and First Quarter 2025 Financial Results

GlobeNewswire May 13, 2025

Metagenomi to Present at Upcoming Scientific Meetings

GlobeNewswire May 2, 2025
View More News ››

Opinion & Analysis (NDAQ:MGX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:MGX)

Buy buddy buy.

This stock is a good one for making big profits.
coolfooldumbguy - January 22, 2025
View more Bullboard ››

Mullen Group Ltd

Mullen Group Ltd

Mullen Group Ltd. provides a range of trucking and logistics services in Canada and the United States. It operates through ...
View More »